Taysha Gene Therapies EBIT

Taysha Gene Therapies (TSHA) currently reports a EBIT of $-150M as of June 2026. That compares with $-93M in the prior-year period — down 64.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Taysha Gene Therapies's EBIT history and peer comparisons.

Taysha Gene Therapies's EBIT decreased from $-93M to $-150M — a 64.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taysha Gene Therapies's EBIT of $-150M is lower than the Healthcare sector average of $23B. That is roughly 100.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Taysha Gene Therapies reported $-150M in EBIT as of June 2026. That compares with $-93M in the prior-year period — down 64.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Taysha Gene Therapies, and consider following TSHA for alerts when major investors trade the stock.